Washington University School Of Medicine
- Address
- 660 South Euclid Avenue 8056
Sponsor Overview
Specializations
Alzheimer’s disease and inherited neurodegeneration
The sponsor’s clinical research centers on Dominantly Inherited Alzheimer Disease (DIAD) and related forms of early-onset Alzheimer’s disease caused by genetic mutations, with attention to disease onset, progression, and clinical impairment.
- Dominantly inherited Alzheimer disease
- Early-onset Alzheimer’s disease
- Genetic mutation–associated dementia risk
Active studies include participants who are at risk for, or living with, inherited Alzheimer’s disease across multiple collaborating sites.
Amyloid and beta-amyloid pathology
Research activity is focused on therapies aimed at reducing amyloid burden and limiting Aβ accumulation, with interest in how amyloid removal influences disease onset and downstream disease expression.
- Amyloid removal
- Aβ accumulation
- Anti-amyloid treatment
The trial portfolio includes evaluation of amyloid-targeted approaches in individuals carrying mutations linked to DIAD.
Biomarkers of Alzheimer’s disease progression
The sponsor supports research on disease-related biomarkers associated with Alzheimer’s pathology, including markers used to track progression and downstream effects of treatment in genetically defined populations.
- Biomarker change
- Downstream Alzheimer’s biomarkers
- Disease progression markers
These studies examine how treatment relates to measurable biological changes alongside clinical outcomes.
Cognitive and clinical impairment
Clinical interest extends to the slowing or prevention of cognitive decline and clinical progression in people with inherited Alzheimer’s disease, with emphasis on preserving function in the earliest stages of disease.
- Cognitive impairment
- Clinical progression
- Dementia prevention
Recruiting studies are examining whether treatment can delay deterioration in individuals with a known Alzheimer’s disease-causing mutation.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| Evaluation of Lecanemab, E2814, and Florquinitau (18F) in Dominantly Inherited Alzheimer's Disease: A Randomized, Double-Blind, Placebo-Controlled Trial |  Germany Ireland Italy Spain The Netherlands | Not Recruiting |
| Evaluation of N-Methyl-2-(4'-Methylaminophenyl)-6-Hydroxybenzothiazole and LY3372993 in Preventing Progression of Dominantly Inherited Alzheimer's Disease |  France Germany Italy Spain | Recruiting |
| Phase IIIb/IV Open-Label Study of Lecanemab in the Prevention and Progression of Dominantly Inherited Alzheimer's Disease | France | Not Recruiting |
Data & Insights
This sponsor works with 5 molecules, of which 2 are not being studied by other sponsors.
This sponsor has worked with 11 sites across their trial portfolio.
Therapeutic Focus
- 1.Nervous System Diseases3 trials449 other sponsors
Partnered Research Centres
11 centres- Address
- Num Voie 47 A 83, 47 Boulevard De L Hopital, 75013 Paris
- Address
- Largo Giovanni Alessandro Brambilla 3, 50134 Florence
- Address
- Cronenburg 2, 1081 GN Amsterdam
- Address
- Rue Michel Polonovski, 59037 Lille
- Address
- 1 Place Du Docteur Joseph Baylac, 31300 Toulouse
- Address
- 1 Rue De Germont, Bp 96031, 76031 Rouen
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Washington University School Of Medicine.
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.